UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Epidemiology and pathogenesis

Authors
Irl B Hirsch, MD
Michael Emmett, MD
Section Editors
David M Nathan, MD
Joseph I Wolfsdorf, MB, BCh
Deputy Editor
Jean E Mulder, MD

INTRODUCTION

Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS, also called hyperosmotic hyperglycemic nonketotic state) are two of the most serious acute complications of diabetes. They each represent an extreme in the hyperglycemic spectrum.

The epidemiology and the factors responsible for the metabolic abnormalities of DKA and HHS in adults will be discussed here. The clinical features, evaluation, diagnosis, and treatment of these disorders are discussed separately. (See "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis" and "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment".)

EPIDEMIOLOGY

Diabetic ketoacidosis (DKA) is characteristically associated with type 1 diabetes. It also occurs in type 2 diabetes under conditions of extreme stress such as serious infection, trauma, cardiovascular or other emergencies, and, less often, as a presenting manifestation of type 2 diabetes, a disorder called ketosis-prone diabetes mellitus. (See "Syndromes of ketosis-prone diabetes mellitus".)

DKA is more common in young (<65 years) patients, whereas hyperosmolar hyperglycemic state (HHS) most commonly develops in individuals older than 65 years [1,2]. The National Diabetes Surveillance Program of the Centers for Disease Control (CDC) estimated that there were 140,000 hospital discharges for DKA in 2009 in the United States, compared to 80,000 in 1988 (figure 1) [2]. Population-based data are not available for HHS. The rate of hospital admissions for HHS is lower than the rate for DKA, and accounts for less than 1 percent of all primary diabetic admissions [1,3-5].

The mortality rate for hyperglycemic crisis declined between 1980 and 2009 (figure 2) [6]. Mortality in hyperglycemic crisis is primarily due to the underlying precipitating illness and only rarely to the metabolic complications of hyperglycemia or ketoacidosis [1,7]. The prognosis of hyperglycemic crisis is substantially worse at the extremes of age and in the presence of coma and hypotension [7-10].

            

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Jul 05 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32:1335.
  2. Centers for Disease Control and Prevention, Diabetes Public Health Resource http://www.cdc.gov/diabetes/statistics/hospitalization_national.htm (Accessed on March 26, 2014).
  3. Fishbein HA, Palumbo PJ. Acute metabolic complications in diabetes. In: Diabetes in America, 2nd ed, National Diabetes Data Group, National Institutes of Health, Bethesda, MD Vol (NIH publ. no: 95-1468), p.283.
  4. Umpierrez GE, Kelly JP, Navarrete JE, et al. Hyperglycemic crises in urban blacks. Arch Intern Med 1997; 157:669.
  5. Kitabchi AE, Fisher JN, Murphy MB, Rumbak MJ. Diabetic ketoacidosis and the hyperglycemic hyperosmolar nonketotic state. In: Joslin's Diabetes Mellitus, 13th, Kahn CR, Weir GC (Eds), Lea & Febiger, Philadelphia 1994. p.738.
  6. Wang J, Williams DE, Narayan KM, Geiss LS. Declining death rates from hyperglycemic crisis among adults with diabetes, U.S., 1985-2002. Diabetes Care 2006; 29:2018.
  7. Gaglia JL, Wyckoff J, Abrahamson MJ. Acute hyperglycemic crisis in the elderly. Med Clin North Am 2004; 88:1063.
  8. Kitabchi AE, Umpierrez GE, Murphy MB. Diabetic ketoacidosis and hyperglycemic hypersmolar state. In: International Textbook of Diabetes Mellitus, 3rd, DeFronzo RA, Ferrannini E, Keen H, Zimmet P (Eds), John Wiley & Sons, Chichester, UK 2004. p.1101.
  9. Wachtel TJ, Silliman RA, Lamberton P. Prognostic factors in the diabetic hyperosmolar state. J Am Geriatr Soc 1987; 35:737.
  10. MacIsaac RJ, Lee LY, McNeil KJ, et al. Influence of age on the presentation and outcome of acidotic and hyperosmolar diabetic emergencies. Intern Med J 2002; 32:379.
  11. Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med 1981; 304:1518.
  12. Diamond MP, Hallarman L, Starick-Zych K, et al. Suppression of counterregulatory hormone response to hypoglycemia by insulin per se. J Clin Endocrinol Metab 1991; 72:1388.
  13. Philippe J. Insulin regulation of the glucagon gene is mediated by an insulin-responsive DNA element. Proc Natl Acad Sci U S A 1991; 88:7224.
  14. Rose BD, Post TW. Clinical physiology of acid-base and electrolyte disorders, 5th, McGraw-Hill, New York 2001. p.794.
  15. Barnes AJ, Bloom SR, Goerge K, et al. Ketoacidosis in pancreatectomized man. N Engl J Med 1977; 296:1250.
  16. Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases. Medicine (Baltimore) 1972; 51:73.
  17. Lorber D. Nonketotic hypertonicity in diabetes mellitus. Med Clin North Am 1995; 79:39.
  18. Hillman K. Fluid resuscitation in diabetic emergencies--a reappraisal. Intensive Care Med 1987; 13:4.
  19. Delaney MF, Zisman A, Kettyle WM. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin North Am 2000; 29:683.
  20. DeFronzo RA, Matzuda M, Barret E. Diabetic ketoacidosis: a combined metabolic-nephrologic approach to therapy. Diabetes Rev 1994; 2:209.
  21. Chupin M, Charbonnel B, Chupin F. C-peptide blood levels in keto-acidosis and in hyperosmolar non-ketotic diabetic coma. Acta Diabetol Lat 1981; 18:123.
  22. Foster DW. Banting lecture 1984. From glycogen to ketones--and back. Diabetes 1984; 33:1188.
  23. Saccà L, Orofino G, Petrone A, Vigorito C. Differential roles of splanchnic and peripheral tissues in the pathogenesis of impaired glucose tolerance. J Clin Invest 1984; 73:1683.
  24. Miles JM, Haymond MW, Nissen SL, Gerich JE. Effects of free fatty acid availability, glucagon excess, and insulin deficiency on ketone body production in postabsorptive man. J Clin Invest 1983; 71:1554.
  25. McGarry JD, Woeltje KF, Kuwajima M, Foster DW. Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. Diabetes Metab Rev 1989; 5:271.
  26. Cook GA, Nielsen RC, Hawkins RA, et al. Effect of glucagon on hepatic malonyl coenzyme A concentration and on lipid synthesis. J Biol Chem 1977; 252:4421.
  27. McGarry JD, Robles-Valdes C, Foster DW. Role of carnitine in hepatic ketogenesis. Proc Natl Acad Sci U S A 1975; 72:4385.
  28. Edgerton DS, Ramnanan CJ, Grueter CA, et al. Effects of insulin on the metabolic control of hepatic gluconeogenesis in vivo. Diabetes 2009; 58:2766.
  29. Owen OE, Trapp VE, Skutches CL, et al. Acetone metabolism during diabetic ketoacidosis. Diabetes 1982; 31:242.
  30. ZIERLER KL, RABINOWITZ D. EFFECT OF VERY SMALL CONCENTRATIONS OF INSULIN ON FOREARM METABOLISM. PERSISTENCE OF ITS ACTION ON POTASSIUM AND FREE FATTY ACIDS WITHOUT ITS EFFECT ON GLUCOSE. J Clin Invest 1964; 43:950.
  31. Kitabchi AE, Fisher JN. Insulin therapy of diabetic ketoacidosis: Physiologic versus pharmacologic doses of insulin and their routes of administration. In: Handbook of Diabetes Mellitus, Brownlee M (Ed), Garland ATPM, New York 1981. p.95.
  32. Khardori R, Soler NG. Hyperosmolar hyperglycemic nonketotic syndrome. Report of 22 cases and brief review. Am J Med 1984; 77:899.
  33. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med 2006; 144:350.
  34. Emmett M, Narins RG. Clinical use of the anion gap. Medicine (Baltimore) 1977; 56:38.
  35. Adrogué HJ, Eknoyan G, Suki WK. Diabetic ketoacidosis: role of the kidney in the acid-base homeostasis re-evaluated. Kidney Int 1984; 25:591.
  36. Owen OE, Licht JH, Sapir DG. Renal function and effects of partial rehydration during diabetic ketoacidosis. Diabetes 1981; 30:510.
  37. Fulop M. The treatment of severely uncontrolled diabetes mellitus. Adv Intern Med 1984; 29:327.
  38. Adrogué HJ, Wilson H, Boyd AE 3rd, et al. Plasma acid-base patterns in diabetic ketoacidosis. N Engl J Med 1982; 307:1603.
  39. Oh MS, Carroll HJ, Goldstein DA, Fein IA. Hyperchloremic acidosis during the recovery phase of diabetic ketosis. Ann Intern Med 1978; 89:925.
  40. Oh MS, Carroll HJ, Uribarri J. Mechanism of normochloremic and hyperchloremic acidosis in diabetic ketoacidosis. Nephron 1990; 54:1.
  41. Viallon A, Zeni F, Lafond P, et al. Does bicarbonate therapy improve the management of severe diabetic ketoacidosis? Crit Care Med 1999; 27:2690.
  42. Latif KA, Freire AX, Kitabchi AE, et al. The use of alkali therapy in severe diabetic ketoacidosis. Diabetes Care 2002; 25:2113.
  43. Lu J, Zello GA, Randell E, et al. Closing the anion gap: contribution of D-lactate to diabetic ketoacidosis. Clin Chim Acta 2011; 412:286.
  44. Katz MA. Hyperglycemia-induced hyponatremia--calculation of expected serum sodium depression. N Engl J Med 1973; 289:843.
  45. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999; 106:399.
  46. Emmett M. Case 6: Diabetes and Acidosis. In: NephSAP: Nephrology Self-Assessment Program: Fluid, Electrolyte, and Acid-Base Disturbances, Sterns RH, Emmett M (Eds), The American Society of Nephrology 2013. Vol 12, No 3, p.191.
  47. Adrogué HJ, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine (Baltimore) 1986; 65:163.
  48. Kreisberg RA. Diabetic ketoacidosis: new concepts and trends in pathogenesis and treatment. Ann Intern Med 1978; 88:681.
  49. Abramson E, Arky R. Diabetic acidosis with initial hypokalemia. Therapeutic implications. JAMA 1966; 196:401.
  50. Atchley DW, Loeb RF, Richards DW, et al. ON DIABETIC ACIDOSIS: A Detailed Study of Electrolyte Balances Following the Withdrawal and Reestablishment of Insulin Therapy. J Clin Invest 1933; 12:297.
  51. Kitabchi AE, Murphy MB. Consequences of insulin deficiency. In: Atlas of Diabetes, 4th, Skyler J. (Ed), Springer US, New York 2012. p.39.
  52. Adrogué HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med 1981; 71:456.
  53. Fulop M. Serum potassium in lactic acidosis and ketoacidosis. N Engl J Med 1979; 300:1087.
  54. Adrogué HJ, Chap Z, Ishida T, Field JB. Role of the endocrine pancreas in the kalemic response to acute metabolic acidosis in conscious dogs. J Clin Invest 1985; 75:798.
  55. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004; 53:2079.
  56. Kitabchi AE, Stentz FB, Umpierrez GE. Diabetic ketoacidosis induces in vivo activation of human T-lymphocytes. Biochem Biophys Res Commun 2004; 315:404.
  57. Luo P, Wang MH. Eicosanoids, β-cell function, and diabetes. Prostaglandins Other Lipid Mediat 2011; 95:1.
  58. McRae JR, Day RP, Metz SA, et al. Prostaglandin E2 metabolite levels during diabetic ketoacidosis. Diabetes 1985; 34:761.
  59. Li J, Huang M, Shen X. The association of oxidative stress and pro-inflammatory cytokines in diabetic patients with hyperglycemic crisis. J Diabetes Complications 2014; 28:662.